The strategies targeting the ghrelin-GHSR system for obesity and metabolic diseases include neutralization of ghrelin, antagonism of ghrelin receptor by its antagonists and inverse agonists, inhibition enzyme involved in ghrelin binding to GHSR, as well as a potential pharmacological target to decrease ghrelin secretion (108). The gene discussed is GHRL; the disease is obesity due to melanocortin 4 receptor deficiency.